###begin article-title 0
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
Global variation in CYP2C8 - CYP2C9 functional haplotypes
###end article-title 0
###begin p 1
These authors contributed equally to this study.
###end p 1
###begin p 2
Current address: University of Chicago, Cancer Research Center
###end p 2
###begin p 3
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 285 291 285 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 381 387 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 412 418 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 518 524 518 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 737 750 737 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8/CYP2C9</italic>
We have studied the global frequency distributions of 10 single nucleotide polymorphisms across 132 kb of CYP2C8 and CYP2C9 in ~2500 individuals representing 45 populations. Five of the SNPs were in non-coding sequences; the other five involved the more common missense variants (4 in CYP2C8, 1 in CYP2C9) that change amino acids in the gene products. One haplotype containing two CYP2C8 coding variants and one CYP2C9 coding variant reaches an average frequency of 10% in Europe; a set of haplotypes with a different CYP2C8 coding variant reaches 17% in Africa. In both cases these haplotypes are found in other regions of the world at < 1%. This considerable geographic variation in haplotype frequencies impacts the interpretation of CYP2C8/CYP2C9 association studies, and has pharmacogenomic implications for drug interactions.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">1</xref>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">2</xref>
###xml 628 629 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R3">3</xref>
The CYP2C8 and CYP2C9 enzymes are members of the cytochrome-P450 CYP2C subfamily of enzymes that are responsible for metabolizing approximately 20% of pharmaceutical drugs used today. CYP2C8 metabolizes various endogenous compounds including arachidonic acid, retinoic acid, and therapeutic drugs such as the widely used chemotherapeutic agent paclitaxel (1). CYP2C8 and CYP2C9 activities overlap in that both enzymes can metabolize arachidonic acid, several non-steroidal anti-inflammatory drugs (NSAIDs), retinoic acid, etc. CYP2C9 separately has been implicated in the metabolism of warfarin, celecoxib, nateglinide etc. (2, 3).
###end p 5
###begin p 6
###xml 5 11 5 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R5">5</xref>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R7">7</xref>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">2</xref>
###xml 803 804 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 954 955 954 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R8">8</xref>
Both CYP2C8 and CYP2C9, the genes coding for these enzymes, are known to be polymorphic (first reported by Dai (4) and Stubbins (5)), and previously published data suggest frequencies of the variant alleles differ among ethnic populations (6). This genetic variation has been shown to have pharmacological implications. The specific functional consequences of the derived variants depend on the substrate. For CYP2C8 264Met, the activity ranges from 0 to 15% compared to 264Ile (7), and for 269Phe the activity for paclitaxel is 50% that of 269Ile (4). At CYP2C9, activity of 144Cys ranges from 10 to 90% of the activity of 144Arg (2). The derived CYP2C8 variants 139Lys and 399Arg, which occur together on the same molecule, produce an enzyme with 15 to 40% of activity compared to the ancestral form (4), depending on substrate. Clearer understanding of the associations can move us a step forward toward individualized drug administration and dosing (8). The two genes are adjacent and within a genomic segment of ~130 kb on chromosome 10.
###end p 6
###begin p 7
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">9</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 470 476 470 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R14">14</xref>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R16">16</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R17">17</xref>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R22">22</xref>
###xml 837 843 837 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 962 968 962 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 1296 1302 1296 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 1419 1425 1419 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 1430 1436 1430 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1456 1458 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R23">23</xref>
###xml 1509 1515 1509 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 751 759 <span type="species:ncbi:9606">patients</span>
###xml 1067 1075 <span type="species:ncbi:9606">patients</span>
Several studies suggest a relationship between CYP2C8 variants, the metabolic index of paclitaxel, and drug-related toxicities (4, 9-13). Though many of those studies showed inter-individual variation in paclitaxel pharmacokinetics, some found no association with specific functional variants at CYP2C8, arguing that those variants were not responsible for the variation. However, other variants at CYP2C8 do seem relevant (13). In addition, ethnic distributions of the CYP2C8 polymorphisms suggest that whichever variant alleles affect paclitaxel metabolism may be more common in a particular ethnic group (14-16). This observation suggests one explanation for varying degrees of toxicities from therapeutic drugs, not limited to paclitaxel, seen in patients of different ethnic ancestries (17-22). In order to test the hypothesis that CYP2C8 variation is related to paclitaxel metabolism and toxicity, we are conducting a clinical trial testing the effects of CYP2C8 haplotypes on drug-related toxicities from paclitaxel in different ethnic groups of breast cancer patients. In designing and conducting a genotype-phenotype association study that can also address inter-ethnic genetic variation, an accurate characterization of global variation in target genes is critical. Since such data for CYP2C8 haplotypes are scanty, we have undertaken to assemble the necessary dataset. Because linkage disequilibrium between CYP2C8 and CYP2C9 has been reported (23) and can be seen in HapMap data, we included some CYP2C9 polymorphisms in this initial study.
###end p 7
###begin p 8
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 177 183 177 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 223 230 223 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 281 296 281 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8 &#8211; CYP2C9</italic>
###xml 447 453 447 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
Using available public databases detailing known common coding and non-coding polymorphisms, we selected and studied 10 Single Nucleotide Polymorphisms (SNPs) of the CYP2C8 and CYP2C9 genes in populations around the world (Table 1). We also estimated haplotype frequencies for the CYP2C8 - CYP2C9 region in these diverse populations. In this paper, we present our initial data demonstrating population-specific allele and haplotype frequencies of CYP2C8 and CYP2C9. This unique data set will be instrumental in future investigations of differences in CYP2C8-mediated drug metabolism among ethnic populations and in designing clinical trials to examine the putative functional impact of genetic polymorphisms of CYP2C8 and CYP2C9.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
CYP2C8-CYP2C9 polymorphism frequencies
###end title 10
###begin p 11
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 135 141 135 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 278 285 278 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 290 298 290 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 768 775 768 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 812 817 <span type="species:ncbi:9606">human</span>
###xml 873 878 <span type="species:ncbi:9606">human</span>
Samples from all ~2,500 individuals were typed for 10 selected SNPs across a region of 132 kb on chromosome 10 encompassing CYP2C8 and CYP2C9. SNPs across the CYP2C8 -CYP2C9 region showed significant allele frequency variation among populations in different geographic regions (Table 1 and Figure 1). None of the 450 Hardy-Weinberg tests (45 populations for 10 SNPs) was significant when multiple testing was taken into account. Thus, our assumption that no cryptic variation interfered with the genotyping assays seems reasonable, though we cannot exclude rare sequence variants that may have interfered with the TaqMan assay resulting in a "null" allele. All of the allele frequency data can be found in ALFRED (the ALlele FREquency Database) using the dbSNP rs# in Table 1 as a keyword. The typing of our non-human primate samples unambiguously identified the ancestral human sequences and was in agreement with the data in the UCSC Genome Browser whenever primate sequences were available.
###end p 11
###begin title 12
Haplotype Frequencies and Linkage disequilibrium
###end title 12
###begin p 13
###xml 40 47 40 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 94 102 94 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R24">24</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R25">25</xref>
###xml 949 962 949 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*139Lys</italic>
###xml 964 977 964 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*399Arg</italic>
###xml 983 996 983 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Cys</italic>
###xml 1103 1116 1103 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*269Phe</italic>
###xml 1270 1283 1270 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*264Ile</italic>
Seventeen common haplotypes were found (Table 2). Estimated haplotype frequencies, plotted in Figure 2, showed that considerable geographic variation exists in haplotype frequencies and that some of the commonly studied functional variants exist on more than one haplotype. Moreover, individual haplotypes contain different combinations of some of the functional variants. Haplotype frequencies are available in ALFRED. There is a complex pattern of pairwise linkage disequilibrium that varies among populations as different haplotypes become more or less frequent (data not shown). Because of the large sample sizes studied in many populations, and the large number of populations, we have a clearer understanding of the genetic variation seen previously in individual populations (24) and at each locus independently (25). Haplotype G, seen at moderate frequencies (0.05 to 0.23) only in Europe and Southwest Asia, contains three coding variants: CYP2C8*139Lys, CYP2C8*399Arg, and CYP2C9*144Cys. Other combinations of those variants occur in haplotypes H and K. In Africa, the combined frequencies of CYP2C8*269Phe-containing haplotypes B, L, and M range from 0.06 to 0.28, but these haplotypes are virtually absent elsewhere in the world. Haplotypes C and N have the CYP2C8*264Ile variant and occur primarily in European populations, but always at low frequencies. Known functional variation is vanishingly rare from Central Asia through East Asia, the Pacific, and the Americas.
###end p 13
###begin title 14
Discussion
###end title 14
###begin title 15
Genetic variation and cancer therapy
###end title 15
###begin p 16
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R26">26</xref>
###xml 861 867 861 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2D6</italic>
###xml 185 190 <span type="species:ncbi:9606">human</span>
###xml 1207 1214 <span type="species:ncbi:9606">patient</span>
Genetic variation has been considered, for some time, to be a major reason for varying susceptibility of individuals to diseases and responses to drugs. Following the completion of the human genome project, the field of pharmacogenomics has captured the imagination of many clinical investigators with the prospect of realizing personalized medicine. Naturally, cancer pharmacologists have invested significant effort and resources into investigating variation among individuals in drug responses and toxicities to chemotherapy agents, as anti-cancer agents often have a narrow therapeutic window and consequences of suboptimal dosing can be detrimental. For example, the implications of variant alleles of dihydropyrimidine dehydrogenase (DPDY) on toxicity of 5-fluorouracil based agents are well described in the literature (26). In addition, polymorphism at CYP2D6 has a predictive value in treatment of breast cancer with tamoxifen, a known substrate of this enzyme. Furthermore, the observation that genetically variant UDP-glucuronosyltransferase 1A1 (UGT1A1) accounts for significant toxicity from irinotecan therapy led US Food and Drug Administration to recommend dose adjustment according to each patient's genomic profile.
###end p 16
###begin p 17
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R27">27</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R12">12</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">9</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11">11</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R28">28</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R29">29</xref>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 25 30 <span type="species:ncbi:9606">human</span>
CYP2C8, one of the first human cytochrome P450 genes to be cloned (27), is well recognized as a significant enzyme in metabolism of numerous therapeutic drugs. Considerable interindividual variation in the metabolism of CYP2C8-specific substrates does exist (12, 13) and this variation has been associated with polymorphism in CYP2C8, which is reported to be the primary enzyme responsible for the elimination and detoxification of paclitaxel. Several association studies have demonstrated a relationship between CYP2C8 variant alleles, the metabolic index of paclitaxel (9, 11, 13, 28-29) and drug-related toxicities. In addition, the ethnic distributions of these polymorphisms had suggested that variant alleles that affect paclitaxel metabolism are more common in particular ethnic groups (6). Extensive ethnic variation in these polymorphisms is now confirmed in this study, but this study does not directly address the relevance of these polymorphisms to paclitaxel metabolism.
###end p 17
###begin title 18
Value of haplotypes
###end title 18
###begin p 19
###xml 446 449 446 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 629 632 629 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1020 1022 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 1055 1061 1055 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 1255 1268 1255 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*399Arg</italic>
###xml 1271 1284 1271 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*139Lys</italic>
###xml 1313 1326 1313 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*264Met</italic>
It has become clear that the analysis of a single SNP in a candidate gene may be grossly inadequate in examining genotype-phenotype relationships. Analysis of haplotypes, the combinations of SNP alleles on one chromosome, can show that certain alleles at different SNPs often or usually occur on the same chromosomes in the population at frequencies greater than expected by chance, i.e., there is linkage disequilibrium. Proteins are encoded in cis from each single chromosome; so the combination of coding variants on a chromosome determines the resulting properties of the enzyme encoded by that chromosome. In addition, many cis-acting regulatory sequences can show variation and determine how much of and in which tissues a protein is synthesized. Hence, haplotype analysis is an essential method for detecting associations between sets of genetic variation and gene function whenever more than a single functional SNP may be involved. The value of haplotypes is illustrated by the work of Rodriguiz-Antona et al. (13) who studied 12 SNPs across the CYP2C8 gene in a moderate sample of 54 unrelated individuals defined loosely only as "Caucasians". They could not find an effect on paclitaxel metabolism associated with heterozygosity for either the CYP2C8*399Arg & CYP2C8*139Lys containing haplotype or the CYP2C8*264Met containing haplotype. However, a different haplotype, labeled B in their study, did have increased 6alpha-hydroxylation of paclitaxel. This haplotype B had derived nucleotides in the promoter region, in intron 2 and in intron 7.
###end p 19
###begin title 20
Haplotypes in our study
###end title 20
###begin p 21
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 229 235 229 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 390 398 390 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 682 690 682 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 471 476 <span type="species:ncbi:9606">human</span>
In this study, we genotyped and haplotyped CYP2C8 and CYP2C9 alleles in a large population cohort representing 45 populations from around the world. This dataset represents the most comprehensive study of frequencies of multiple CYP2C8 and CYP2C9 SNPs in diverse populations thus far. We observed striking allele frequency variation of individual polymorphisms among different populations (Figure 1, data in ALFRED). This finding is in line with general expectations for human polymorphisms and long standing clinical observation of ethnic differences in response to and toxicity from various drugs metabolized by the CYP2C subfamily. The global variation in haplotype frequencies (Figure 2, data in ALFRED) similarly shows large inter-population variation. For example, haplotype G reaches an average frequency of 0.10 in Europe, while its frequency averages less than 0.01 in other regions of the world. It is reasonable to hypothesize that some of these population specific distributions of individual alleles and/or haplotypes may have functional impact, resulting in inter-individual and inter-ethnic heterogeneity in drug metabolism, response, and toxicity.
###end p 21
###begin title 22
Linkage disequilibrium between CYP2C9 and CYP2C8
###end title 22
###begin p 23
###xml 226 239 226 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Cys</italic>
###xml 241 254 241 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*399Arg</italic>
###xml 256 269 256 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*139Lys</italic>
###xml 328 335 328 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 339 347 339 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 356 369 356 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*399Arg</italic>
###xml 374 387 374 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*139Lys</italic>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 432 445 432 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Cys</italic>
###xml 504 517 504 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Cys</italic>
###xml 728 741 728 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Cys</italic>
###xml 770 776 770 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 787 794 787 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 883 896 883 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Cys</italic>
###xml 996 1002 996 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 1079 1085 1079 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 1110 1123 1110 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Cys</italic>
###xml 1309 1315 1309 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1341 1347 1341 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 1426 1428 1426 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R29">29</xref>
###xml 1610 1611 1610 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">1</xref>
###xml 1613 1615 1613 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R31">31</xref>
Three of the coding missense variants are especially interesting from a population genetics perspective and have significant research implications, and potentially clinical implications, in European populations. The three are CYP2C9*144Cys, CYP2C8*399Arg, CYP2C8*139Lys. These three occur in only three haplotypes: G, H, and K (Table 2and Figure 2). While CYP2C8*399Arg and CYP2C8*139Lys are always seen in cis, they occur with the CYP2C9*144Cys variant in haplotype G and without it in haplotype K. The CYP2C9*144Cys allele occurs by itself in haplotype H. Only in the European and Southwest Asian populations do we see haplotypes G, H, and K simultaneously present. In these populations on average 90% of chromosomes with the CYP2C9*144Cys allele also carry these two CYP2C8 variants (Table 3). Thus, an exploratory study in Europeans and/or Southwest Asians of association of the CYP2C9*144Cys allele with a trait (disease risk, therapy response, etc.) will usually be simultaneously studying CYP2C8 variation. Conversely, on average 89% of chromosomes with either of the two CYP2C8 variants also carry the CYP2C9*144Cys allele. This strong association implies that if any of the three relevant SNPs gives a positive result in a case-control study, it will be difficult to distinguish any association with CYP2C9 from an association with CYP2C8 and vice versa. Given studies of CYP2C8/CYP2C9 pharmacokinetics of ibuprofen (29), it is likely that haplotype effects will be seen for other joint substrates of CYP2C8 & CYP2C9, such as verapamil, isotretinoin, retinoic acid, arachidonic acid, and fluvastatin (1, 31). Moreover, given this pattern of linkage disequilibrium, there could well be other important variation yet to be identified, especially on haplotype G.
###end p 23
###begin title 24
Other functional variation?
###end title 24
###begin p 25
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 184 197 184 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*269Phe</italic>
###xml 454 467 454 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*269Phe</italic>
###xml 968 974 968 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 1009 1015 1009 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
Previous studies of variation at CYP2C8 and CYP2C9 may not have uncovered the true wealth of African-specific functional variation. For example, haplotypes B, L, and M, containing the CYP2C8*269Phe allele, reach a combined average frequency of 0.17 in Africa, while occurring at less than 0.01 in the rest of the world. Thus, it is also clear that 17% of African patients may have a very different drug response, due to their haplotypes with the variant CYP2C8*269Phe allele. In addition, at least three other haplotypes (D, F, and O) reach an average frequency of greater than 0.10 in Africa, but are less frequent, on average, in Europe and East Asia, where most previous resequencing efforts have been concentrated. Resequencing a number of African individuals with these haplotypes may discover frequent coding variants which may provide explanations for pharmacogenomic diversity unexplained by the Arg139Lys, Met264Ile, Ile269Phe, and Lys399Arg polymorphisms in CYP2C8 and the Arg144Cys polymorphism in CYP2C9. As we approach the ability to truly examine each individual's DNA sequence to predict optimal therapy, we will need to know what actual genetic variation exists in the population in order to interpret an individual's DNA sequence.
###end p 25
###begin p 26
###xml 597 619 597 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD1">Supplementary Material</xref>
As a further guide to optimizing design of resequencing efforts to identify additional sequence variation, it is useful to identify the distinct evolutionary sequences that represent lineages that may have independently accumulated variation. To that end we have examined the existing haplotypes we have identified in conjunction with knowledge of the ancestral sequences. Three segments of this 132kb segment of chromosome 10 show no obligate crossover products. The 17 common haplotypes can be explained by a series of historical crossovers among the different haplotypes of the three segments (Supplementary Material). In addition to testing multiple populations for whatever new polymorphic variation is found, we need to test more existing SNPs in known regulatory regions as well as those that might have less obvious functional consequences: synonymous coding SNPs that could affect mRNA folding and/or mRNA stability as well as intronic SNPs that could affect splicing or may have regulatory function. SNPs recently implicated in paxitaxel pharmacokinetics have especially high priority (e.g. 13). Whatever complexity additional SNPs may add to the initial haplotype frequency data we have presented here, additional SNPs can only subdivide the haplotypes defined by the 10 SNPs we have studied and cannot alter the frequencies of the existing combinations of alleles at the missense SNPs.
###end p 26
###begin title 27
Lack of comparability across studies
###end title 27
###begin p 28
###xml 35 37 35 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 299 305 299 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 572 589 572 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD1">supplemental data</xref>
The Rodriguiz-Antona et al. study (13) also illustrates a general problem: the need to consider these loci as haplotypes based on a common set of polymorphisms with each haplotype treated as an allele. We are not able to rigorously compare our 8-SNP haplotypes across CYP2C8 (ignoring the 2 SNPs at CYP2C9) with the Rodriguiz-Antona et al. (13) 12-SNP haplotypes because only four SNPs were studied in common. Based on the four SNPs studied in common their haplotype B (which shows altered paclitaxel metabolism) falls within a pool of 10 of our 17 common haplotypes (see supplemental data). This pool of haplotypes has a total frequency ranging from 68% to 85% among our 10 specific European samples. An obvious future study for us is to add into our dataset the SNPs that specifically identified their haplotype B to allow meaningful comparison of data sets. Similarly, many other studies of CYP2C8 have used only subsets or overlapping sets of polymorphisms to define the relevant haplotypes. We believe that a database of dense marker coverage of each gene in multiple populations will be necessary to define what haplotypes are common in different parts of the world. Such data allow reasonable inference from a few markers of the actual haplotypes present in a future study and allow meaningful comparisons among studies. Our study is an initial step towards such a database.
###end p 28
###begin p 29
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C18</italic>
###xml 273 280 273 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C19</italic>
We believe this study also provides a basis for systematic searches for additional functional variation that may occur at a moderate frequency in one or more regions of the world. When more SNPs are systematically typed across CYP2C8 and CYP2C9 (and the nearby CYP2C18 and CYP2C19), a better picture of the population genetic structure of this region will emerge.
###end p 29
###begin title 30
Methods
###end title 30
###begin title 31
Markers studied
###end title 31
###begin p 32
###xml 204 210 204 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 465 472 465 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 530 536 530 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 548 554 548 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 578 584 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 643 649 643 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R23">23</xref>
###xml 697 703 697 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 910 916 910 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 997 1003 997 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
Using dbSNP (), the International HapMap Project (), Applied Biosystems' SNPBrowser (), and the UCSC Genome Browser () we compiled data on confirmed SNPs, including the more common functional variants at CYP2C8 and CYP2C9. From this set we selected 10 SNPs likely to be reasonably heterozygous in some part of the world, or confirmed to have functional consequences and frequencies in the polymorphic range, i.e., the frequency of the less common allele was >0.01 (Table 1). Five of the ten SNPs were coding SNPs (cSNPs), four in CYP2C8 and one in CYP2C9. We emphasized SNPs at CYP2C8 but, based on some reports of linkage disequilibrium with CYP2C9 (6, 23), we included two SNPs at the 5' end of CYP2C9. The five non-coding SNPs were chosen to show different frequency patterns among populations already studied in an attempt to maximize haplotype diversity with a small number of SNPs. The final set covered CYP2C8 from just upstream of the coding sequence to just shy of the last exon. The two CYP2C9 SNPs extended the total interval covered to just past the 5' end of CYP2C9. We did not study variants that had only been reported in single individuals.
###end p 32
###begin title 33
Populations studied
###end title 33
###begin p 34
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R32">32</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R35">35</xref>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R35">35</xref>
###xml 1318 1398 1318 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pan troglodytes, Pan paniscus, Gorilla gorilla, Pongo pygmaeus, and Hylobates sp</italic>
###xml 1046 1051 <span type="species:ncbi:9606">human</span>
###xml 1318 1333 <span type="species:ncbi:9598">Pan troglodytes</span>
###xml 1335 1347 <span type="species:ncbi:9597">Pan paniscus</span>
###xml 1349 1364 <span type="species:ncbi:9593">Gorilla gorilla</span>
###xml 1366 1380 <span type="species:ncbi:9600">Pongo pygmaeus</span>
We used our resource at Yale University that contains DNA of more than 2500 unrelated individuals representing populations from around the world; this resource has been used for many genetic studies (32-35). The 45 populations represented in the present study include 10 African (Biaka, Mbuti, Yoruba, Ibo, Hausa, Chagga, Masai, Sandawe, Ethiopian Jews, and African Americans); 3 Southwest Asian (Yemenite Jews, Druze, Samaritans); 10 European (Adygei, Chuvash, Vologda Russians, Archangel Russians, Ashkenazi Jews, Finns, Hungarians, Danes, Irish, and European Americans); 2 Northwest Asian (Komi Zyriane, Khanty), 8 East Asian (Chinese from San Francisco, Taiwan Han Chinese, Hakka, Koreans, Japanese, Ami, Atayal, Cambodians), 1 Northeast Siberian (Yakut), 2 from Pacific Islands (Nasioi Melanesians, Micronesians), 4 North American (Cheyenne, Pima from Arizona, Pima from Mexico, Maya), and 4 South American (Quechua, Ticuna, Rondonia Surui, Karitiana). All subjects gave informed consent under protocols approved by the committees governing human subjects research relevant to each of the population samples. Sample descriptions and sample sizes can be found in ALFRED, the ALlele FREquency Database (), and in a previous publications (35). We also typed three individuals from each of five other primate groups: Pan troglodytes, Pan paniscus, Gorilla gorilla, Pongo pygmaeus, and Hylobates sp.
###end p 34
###begin title 35
Marker Typing
###end title 35
###begin p 36
###xml 109 116 109 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
All markers were typed using TaqMan assays purchased from Applied Biosystems; the assay numbers are given in Table 1. Manufacturer's protocols were followed, with reaction volumes reduced to 3microl, run in 384-well plates and read on an AB9700HT using Applied Biosystems' SDS (sequence detection system) software.
###end p 36
###begin title 37
Statistical Analyses
###end title 37
###begin p 38
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R36">36</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R37">37</xref>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R38">38</xref>
###xml 1179 1185 1179 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1219 1225 1219 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
Genotype and allele frequencies for each individual site were estimated by simple gene counting assuming co-dominant inheritance with no silent alleles; data were consistent with that assumption. Hardy-Weinberg ratios were tested by chi-square and by an "exact" test using 1000 simulations when small (<5) observed numbers were present for one or more genotype in a population. Haplotypes were estimated using PHASE (36) and fastPHASE (37) with subpopulation information. There were <1% discrepancies in estimation between the two methods; discrepancies were individually examined. Differences in estimation of missing data for a SNP were responsible for all phasing discrepancies, with the data from PHASE generally being more consistent (fewer rare haplotypes), so the PHASE haplotypes were used. Genotypes of individuals were analyzed by HAPLOT (38) for identifying regions with strong linkage disequilibrium (LD), sometimes called "LD blocks" (data not shown). We have not attempted to relate these haplotypes to the CYPAlleles nomenclature () because we have not studied all of the SNPs used in some of the definitions and, as demonstrated here, the allelic definitions for CYP2C9 are not independent of those for CYP2C8.
###end p 38
###begin title 39
Supplementary Material
###end title 39
###begin title 40
Acknowledgements
###end title 40
###begin p 41
###xml 118 124 <span type="species:ncbi:9606">people</span>
This work was funded in part by NIH grants AA009379 and GM57672 (to KKK). We also acknowledge and thank the following people who helped assemble the samples from the diverse populations: C. Barta, F.L. Black, L.L. Cavalli-Sforza, K. Dumars, J. Friedlaender, E.L. Grigorenko, N.J. Karoma, K. Kendler, J.J. Kim, W. Knowler, R.-B. Lu, A. Odunsi, F. Okonofua, F. Oronsaye, J. Parnas, L. Peltonen, L. O. Schulz, Z. Tarnok, D. Upson, K. Weiss, and O.V. Zhukova. Some of the cell lines were obtained from the National Laboratory for the Genetics of Israeli Populations, Tel Aviv University; the African American samples were obtained from the Coriell Institute for Medical Research. Special thanks are due to the many hundreds of individuals who volunteered to give blood samples.
###end p 41
###begin p 42
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest / Disclosure</bold>
Conflict of Interest / Disclosure
###end p 42
###begin p 43
The authors declare no conflict of interest.
###end p 43
###begin p 44
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Electronic resources</bold>
Electronic resources
###end p 44
###begin p 45
dbSNP:
###end p 45
###begin p 46
HapMap:
###end p 46
###begin p 47
AB SNPBrowser:
###end p 47
###begin p 48
ALFRED:
###end p 48
###begin p 49
UCSC Genome Browser:
###end p 49
###begin title 50
References
###end title 50
###begin article-title 51
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance
###end article-title 51
###begin article-title 52
The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations
###end article-title 52
###begin article-title 53
Clinical consequences of cytochrome P450 2C9 polymorphisms
###end article-title 53
###begin article-title 54
###xml 17 22 <span type="species:ncbi:9606">human</span>
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
###end article-title 54
###begin article-title 55
###xml 24 29 <span type="species:ncbi:9606">human</span>
Genetic analysis of the human cytochrome P450 CYP2C9 locus
###end article-title 55
###begin article-title 56
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals
###end article-title 56
###begin article-title 57
Functional Role of Ile264 in CYP2C8: Mutations Affect Haem Incorporation and Catalytic Activity
###end article-title 57
###begin article-title 58
Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk
###end article-title 58
###begin article-title 59
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer
###end article-title 59
###begin article-title 60
Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism
###end article-title 60
###begin article-title 61
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
###end article-title 61
###begin article-title 62
###xml 105 110 <span type="species:ncbi:9606">human</span>
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes
###end article-title 62
###begin article-title 63
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism
###end article-title 63
###begin article-title 64
A novel intronic mutation that may affect genotyping result of CYP2C8 by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) is strongly associated with CYP2C8*3 in a South American population
###end article-title 64
###begin article-title 65
Pharmacogenetics of the major polymorphic metabolizing enzymes
###end article-title 65
###begin article-title 66
Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping
###end article-title 66
###begin article-title 67
###xml 51 58 <span type="species:ncbi:9606">patient</span>
Severe pulmonary complications in African-American patient after bortezomib therapy
###end article-title 67
###begin article-title 68
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
###end article-title 68
###begin article-title 69
Doxorubicin cardiotoxicity in African Americans
###end article-title 69
###begin article-title 70
Attenuation of isoproterenol-mediated vasodilatation in blacks
###end article-title 70
###begin article-title 71
Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis
###end article-title 71
###begin article-title 72
Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics
###end article-title 72
###begin article-title 73
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
###end article-title 73
###begin article-title 74
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population
###end article-title 74
###begin article-title 75
Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes
###end article-title 75
###begin article-title 76
Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy
###end article-title 76
###begin article-title 77
Pharmacogenetics of the cytochromes P450
###end article-title 77
###begin article-title 78
Peripheral neuropathy induced by Paclitaxel: recent insights and future perspectives
###end article-title 78
###begin article-title 79
Individualized pharmacotherapy with paclitaxel
###end article-title 79
###begin article-title 80
Interindividual variability in ibuprofeno pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms
###end article-title 80
###begin article-title 81
###xml 40 45 <span type="species:ncbi:9606">human</span>
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
###end article-title 81
###begin article-title 82
###xml 32 37 <span type="species:ncbi:9606">human</span>
Implications of biogeography of human populations for 'race' and medicine
###end article-title 82
###begin article-title 83
Haplotype evolution of SLITRK1, a candidate gene for Gilles de la Tourette syndrome
###end article-title 83
###begin article-title 84
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase
###end article-title 84
###begin article-title 85
Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene
###end article-title 85
###begin article-title 86
Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-Data Imputation
###end article-title 86
###begin article-title 87
A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase
###end article-title 87
###begin article-title 88
HAPLOT: a graphical comparison of haplotype blocks, tagSNP sets and SNP variation for multiple populations
###end article-title 88
###begin title 89
Figures and Tables
###end title 89
###begin title 90
A graphical depiction of the frequencies of the ancestral alleles at the 10 SNPs studied in the 45 populations
###end title 90
###begin p 91
The figure illustrates the frequencies of these alleles in 45 different populations (listed across the bottom) from around the world. Populations are ordered generally as Africa, Europe, East Asia, Americas.
###end p 91
###begin title 92
###xml 0 13 0 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9-CYP2C8</italic>
CYP2C9-CYP2C8 haplotype frequencies
###end title 92
###begin p 93
###xml 47 56 47 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8-C9</italic>
###xml 217 225 217 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 391 398 391 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
The frequencies of the 17 common haplotypes of CYP2C8-C9 SNPs. The figure illustrates the frequencies of these haplotypes in 45 different populations listed from top to bottom on the left side in the same order as in Figure 1. The length of each colored bar represents the frequency of the corresponding haplotype in that population. The allelic compositions for the haplotypes are given in Table 2; the frequencies are in ALFRED. Haplotypes that are rare (less than 5%) in all populations are combined into a residual class. Note that coding variants can occur in different combinations and as part of different haplotypes.
###end p 93
###begin title 94
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8</italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
The 10 polymorphisms (SNPs) studied across CYP2C8 and CYP2C9
###end title 94
###begin p 95
The amino acid changes are indicated for those SNPs in exons. For the non-synonymous (functional) SNPs the most closely corresponding CYPAllele designation is given in parentheses
###end p 95
###begin p 96
###xml 74 82 74 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
The haplotype compositions of the 17 common haplotypes, color coded as in Figure 2
###end p 96
###begin title 97
###xml 29 42 29 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Lys</italic>
###xml 47 60 47 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*399Arg</italic>
###xml 65 79 65 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> CYP2C8*139Lys</italic>
The interdependencies of the CYP2C9*144Lys and CYP2C8*399Arg plus CYP2C8*139Lys alleles in European and Southwest Asian populations
###end title 97
###begin p 98
###xml 65 78 65 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Lys</italic>
###xml 128 141 128 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*399Arg</italic>
###xml 147 160 147 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*139Lys</italic>
###xml 276 289 276 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*399Arg</italic>
###xml 295 308 295 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C8*139Lys</italic>
###xml 358 371 358 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*144Lys</italic>
For each population the first column gives the proportion of the CYP2C9*144Lys chromosomes in the population that also have the CYP2C8*399Arg plus CYP2C8*139Lys alleles (always seen together) on the same chromosome. The second column gives the converse: the proportion of the CYP2C8*399Arg plus CYP2C8*139Lys chromosomes in the population that also have the CYP2C9*144Lys allele on the same chromosome. The numbers are calculated from the frequencies of the relevant haplotypes, represented as Freq(G), Freq(H), and Freq(K)
###end p 98

